Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Metformin; Rosiglitazone; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Continuously enrolled in the health insurance plan to ensure complete claims coverage

• At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx)

• Aged 18 years or older at the index date

• At least 6 months of baseline period prior to the index date

• At least 1 claim for MET during the baseline period

• At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date

Exclusion Criteria:

• At least 1 claim for insulin or sulfonylurea in the baseline period

• At least 1 claim with a diagnosis of congestive heart failure in the baseline period